Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AMN Healthcare (AMN) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

AMN Healthcare's (AMN) first-quarter results are likely to reflect solid demand in some of the areas of its business.

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex Pharmaceuticals' (VRTX) Q1 earnings call, investors are most likely to focus on the sales performance of its triple combo CF drug Trikafta/Kaftrio and updates on the non-CF pipeline.

Will Eylea, Dupixent Buoy Regeneron's (REGN) Q1 Earnings?

by Zacks Equity Research

Regeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.

Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

by Zacks Equity Research

Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.

Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates

by Zacks Equity Research

Novo Nordisk (NVO) reports better-than-expected results for Q1. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

How Will Pfizer's (PFE) Key Drugs Perform in Q1 Earnings?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 products are likely to have driven sales in the first quarter.

Is a Beat Likely for Moderna (MRNA) This Earnings Season?

by Zacks Equity Research

Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the first-quarter earnings call that can help it to reduce its dependence on Spikevax.

Sweta Killa headshot

5 Best Stocks in Nasdaq ETF That Gained in April

by Sweta Killa

The tech-heavy Nasdaq Composite Index logged in the worst month since 2008, having fallen 15%.

DaVita (DVA) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Supply shortage along with pandemic-led incremental mortality rate is likely to have weighed on DaVita's (DVA) first-quarter top line.

The Zacks Analyst Blog Highlights Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen

by Zacks Equity Research

Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen have been included in this Analyst Blog.

AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AstraZeneca's (AZN) first-quarter results reflect a beat on both counts (revenues and earnings). AZN maintains its 2022 guidance.

Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Emergent's (EBS) first-quarter 2022 earnings miss estimates while sales beat the mark. EBS suspends its CDMO guidance for 2022 until it gets a better picture of the COVID-19 vaccine requirements.

Bristol-Myers (BMY) Q1 Earnings Beat Estimates, Guidance Down

by Zacks Equity Research

Bristol-Myers (BMY) earnings beat estimates in the first quarter of 2022. Sales jump year over year on the back of Eliquis and new products.

Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales

by Zacks Equity Research

Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.

Indrajit Bandyopadhyay headshot

5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates

by Indrajit Bandyopadhyay

Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repligen (RGEN) Q1 Earnings and Sales Beat Estimates, Stock Up

by Zacks Equity Research

Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022

BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Biomarin Pharmaceutical's (BMRN) first-quarter earnings and sales beat estimates. BMRN also raises its financial guidance for 2022 Voxzogo sales by $10 million.

Eli Lilly (LLY) Beats on Q1 Earnings, Ups Sales View, Stock Rises

by Zacks Equity Research

Eli Lilly (LLY) beats first-quarter estimates for both earnings and sales and ups its sales outlook for 2022. The stock rises in pre-market trading.

Amgen's (AMGN) Q1 Earnings Top, Stock Down on IRS Tax Dispute

by Zacks Equity Research

Amgen (AMGN) beats Q1 estimates for earnings and sales. The stock declines on the announcement of litigation and tax dispute with the IRS.

Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPGP

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) closed at $267.25 in the latest trading session, marking a -0.16% move from the prior day.

Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Incyte's (INCY) top line is likely to have been driven in the first quarter by the sales of its lead drug, Jakafi.

BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q2 sales.

Boston Scientific (BSX) Q1 Earnings Top, 2022 Revenue View Up

by Zacks Equity Research

Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.